NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Lantern Pharma's AI-Driven Cancer Drug Development Platform
TL;DR
Lantern Pharma's AI platform gives pharmaceutical companies a competitive edge by significantly reducing drug development timelines and costs in oncology.
Lantern Pharma's RADR platform uses machine learning algorithms to analyze billions of data points, model molecules, and predict patient responses for drug discovery.
Lantern Pharma's AI-driven approach accelerates cancer treatment development, potentially bringing life-changing therapies to hundreds of thousands of patients worldwide faster.
Lantern Pharma's AI platform reads scientific papers and suggests new drug uses, compressing years of research into accelerated discovery timelines.
Found this article helpful?
Share it with your network and spread the knowledge!
Lantern Pharma is an AI-driven cancer drug developer that uses machine learning to discover new therapies, reposition existing molecules, and target high-unmet-need oncology indications, transforming the cost and timeline of oncology drug development.
The RADR® platform self-learns, reads scientific papers, models molecules, predicts patient response, and suggests new indications by leveraging over 200 billion oncology-focused data points and 200+ advanced machine learning algorithms.
AI is compressing development timelines and cost structures across oncology, enabling faster, cheaper, and more personalized treatments while significantly reducing the time and cost of drug development.
Lantern has three clinical-stage oncology candidates, including a Phase 2 trial for non-smoker non-small cell lung cancer and a program targeting cancers with DNA damage repair deficiency using synthetic lethality.
The company expects upcoming data milestones from its LP-184 program and plans to roll out its AI platform commercially to drug developers worldwide.
The AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and could provide life-changing therapies to hundreds of thousands of cancer patients worldwide.
The interview with CEO Panna Sharma was recorded at the New York Stock Exchange and featured on FintechTV.
The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN, and the full interview can be viewed at https://ibn.fm/ZvbMK.
The company's pipeline spans multiple cancer indications including both solid tumors and blood cancers, and includes an antibody-drug conjugate (ADC) program alongside its lead development programs.
Curated from InvestorBrandNetwork (IBN)
